The overall objective of the project is to devel+op TPS-100 as a first treatment of ARSACS and to identify a second generation drug based on efficacy and knowledge of receptor pharmacology of TPS-100. Our goal is to synthesize a directed library of compounds with varying Kv channel pharmacology with the goal of enhancing activity at Kv1.2, 1.3, 1.4 relative to Kv1.5 and Kv1.1 which are believed to be associated with potential side effects (Table 2).
Duration: one year
Shawn Maddaford, Talon Pharmaceutical Services Inc.
2660 Speakman Drive, Rm A-61 Mississauga, ON L5K 2L1
Tel:(416) 479-0738 ext 102